BILL O'NEIL ARCHIVES: Analysis Of The Greatest Stocks Of All Time Shares of Cidara Therapeutics (CDTX), which have already rocketed more than 173% this year, surged to a five-year high Wednesday on plans to expand testing for its non-vaccine flu prevention drug. Following a meeting with the Food and Drug Administration, Cidara accelerated plans to start Phase 3 testing by six months. The company's goal is to time out its testing with the flu season in the Northern Hemisphere. The agency also encouraged the ...